Strategic Acquisition HD Biosciences is part of WuXi AppTec, a leading global pharma and biotech platform, which enhances its capability to offer integrated drug discovery services and expands its market reach, presenting cross-selling opportunities within WuXi’s extensive network.

Growing Market Presence With annual revenues estimated between 25M and 50M dollars and operations spanning China and the US, HD Biosciences is positioned as a regional leader in preclinical CRO services, making it a prime target for partnerships with biotech firms seeking high-quality early-stage drug discovery support.

Research Capabilities Specialized in target validation, pharmacology, and lead discovery, HD Biosciences offers comprehensive services that could complement the offerings of companies looking to expand their preclinical R&D portfolios or enhance their early-stage pipeline.

Innovation and Technology Utilizing advanced tech like ASP.NET and Google Analytics, alongside a focus on biology-driven research, positions HD Biosciences as a technologically savvy partner that can adopt and integrate new digital solutions to optimize research workflows and client engagement.

Industry Leadership Reputable for consistent, high-quality outcomes, HD Biosciences’ recognized leadership in preclinical research creates opportunities to collaborate on high-impact projects, especially with pharmaceutical companies aiming for dependable early-stage research partner.